COAG — Hemab Therapeutics Holdings Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Hemab Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 88.3 | 185 |
| Net Total Receivables | 1.58 | 2.63 |
| Prepaid Expenses | ||
| Total Current Assets | 93.2 | 193 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 2.57 | 1.7 |
| Other Long Term Assets | ||
| Total Assets | 96.3 | 195 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 6.68 | 10.7 |
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 7.8 | 11.3 |
| Redeemable Preferred Stock | ||
| Non Redeemable Preferred Stock | ||
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | 88.5 | 184 |
| Total Liabilities & Shareholders' Equity | 96.3 | 195 |
| Total Common Shares Outstanding |